Scientists Reportedly Reprogram Leukemia Cells to Self-Destruct and Trigger an Immune Response in Preclinical Models

A post says Institut Pasteur researchers combined three clinically used compounds to work around a missing molecular component in malignant B-cell leukemia and activate an immune response. It describes imaging in preclinical models showing immune cells moving in and completely clearing the disease. The approach has not been tested in patients; the post suggests existing compounds could speed clinical evaluation.